Reta glucagon-like peptide-1 (GLP-1) receptor agonists provide a groundbreaking approach to diabetes management. These innovative therapies work by mimicking the inherent actions of GLP-1, a hormone produced by the gut in response to food. By activating GLP-1 receptors in the pancreas, these compounds enhance insulin secretion and inhibit glucagon

The burgeoning landscape of novel treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual approach agonists targeting the GLP-1 and GIP receptors. While sharing a similar therapeutic goal – improving glycemic control and promoting significant weight reduction – they exhibit intriguing contrasts in th